Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 8, 2026Reported sale · Form 4LAUREN RIKER, Senior Vice President, Finance · $217.9KOpen the filing ↗
- Oct 8, 2026Notice of sale · Form 144RIKER LAUREN · Officer · $217.9KOpen the filing ↗
- Oct 8, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record1,21225 flagged findings
Reported transactions (Form 4)80since Oct 6, 2023 · and 17 other holdings
Corporate events (8-K)30since Mar 22, 2023
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-04-30share offering or dilution eventrecentOpen filing ↗“…10,891 9,002 Other accrued operating expenses 10,576 12,864 Compensation and benefits 25,812 37,841 Accrued interest 2,308 782…”
+1 more passage from the same document
- “…782 Product returns and wholesaler service fees 11,014 11,554 Total $ 84,957 $ 95,601 NOTE 9— DEBT The carrying value of the…”
- 2026-04-30capital return (buybacks/dividends)recentOpen filing ↗“…Other Comprehensive Income Balance at December 31, 2024 $ 190 $ 153 $ 343 Net unrealized loss on investments, net of tax…”
+1 more passage from the same document
- “…investments, net of tax (1) ( 86 ) — ( 86 ) Foreign currency translation adjustments — 1,094 1,094 Balance at March 31, 2025 $ 104 $…”
- 2026-04-30merger or acquisition eventrecentOpen filing ↗“…solely in its capacity as representative for the former securityholders of MyoScience and certain other defendants, seeking…”
+1 more passage from the same document
- “…merger agreement for the MyoScience Acquisition (the “MyoScience Merger Agreement”), specifically related to the achievement of…”
- 2026-02-26share offering or dilution eventrecentOpen filing ↗“…and Indebtedness Servicing our indebtedness requires a significant amount of cash, and we may not have sufficient cash flow from…”
+1 more passage from the same document
- “…our 2025 Notes. The partial repurchase of the 2025 Notes was completed with our net proceeds from the issuance of the 2029 Notes. For…”
- 2026-02-26capital return (buybacks/dividends)recentOpen filing ↗“…of our assets as well as prohibitions on our ability to create liens, pay dividends, redeem our stock or make investments.…”
+1 more passage from the same document
- “…in debt covenants), regulatory restrictions and alternative uses of capital. There can be no assurance that repurchases will be…”
- 2026-02-26regulatory investigationrecentOpen filing ↗“…postsurgical local analgesia that was approved by the FDA in March 2021 and the indications for adductor canal block and sciatic…”
- 2026-02-26Department of Justice inquiryrecentOpen filing ↗“…that was approved by the FDA in March 2021 and the indications for adductor canal block and sciatic nerve block in the popliteal…”
+1 more passage from the same document
- “…a subpoena from the U.S. Department of Justice, U.S. Attorney’s Office for the District of New Jersey, requiring the production of a…”
- 2026-02-26merger or acquisition eventrecentOpen filing ↗“…utilizing GQ Bio’s HCAd gene therapy vector platform and assets with disease-modifying potential in prevalent musculoskeletal…”
+1 more passage from the same document
- “…platform and assets with disease-modifying potential in prevalent musculoskeletal diseases. For more information, see Note 4, GQ…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 1,212)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 13, 26SCHEDULE 13D/A ↗Stake with intent to influence · amendment new
- Oct 9, 26Form 4 ↗Insider transaction
- Oct 8, 26Form 144 ↗Notice of proposed sale
- Oct 8, 268-K ↗Current report · Entered a material agreement
- Aug 18, 26Form 4 ↗Insider transaction
- Aug 17, 26Form 144 ↗Notice of proposed sale
- Aug 7, 26SCHEDULE 13G ↗Passive stake · STATE STREET CORPORATION · 5.2% · event on Jun 30, 26
- Aug 4, 2610-Q ↗Quarterly report
- Aug 4, 268-K ↗Current report · Results
- Jun 30, 268-K ↗Current report · Entered a material agreement
- Jun 12, 26Form 144 ↗Notice of proposed sale
Insider transaction · 9 Form 4 filingsshow all 9hide
- Jun 12, 26Form 4 ↗Insider transaction
- Jun 12, 26Form 4 ↗Insider transaction
- Jun 12, 26Form 4 ↗Insider transaction
- Jun 12, 26Form 4 ↗Insider transaction
- Jun 12, 26Form 4 ↗Insider transaction
- Jun 12, 26Form 4 ↗Insider transaction
- Jun 12, 26Form 4 ↗Insider transaction
- Jun 12, 26Form 4 ↗Insider transaction
- Jun 12, 26Form 4 ↗Insider transaction
- Jun 12, 26Form 3 ↗Insider transaction
- Jun 11, 26Form 144 ↗Notice of proposed sale
- Jun 11, 268-K ↗Current report · A senior executive left or was appointed
1,212 filings on record, the oldest from Feb 2, 11.
Listing the 25 most recent filings of the 1,212 on record.
35049
- Oct 8, 26Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Jun 30, 26Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Jun 11, 26A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- Jan 28, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jul 10, 25Restructuring plan with committed costs+2 more in the same filing8-K 2.05 ↗
- Jul 7, 25A material agreement was terminated+3 more in the same filing8-K 1.02 ↗
- Jun 13, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Apr 7, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
6 senior executive changes2024 – 2025show all 6hide
- Jan 30, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jan 21, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Nov 6, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Oct 21, 24A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Sep 27, 24A senior executive left or was appointed8-K 5.02 ↗
- Jun 13, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- May 14, 24Took on a new financial obligation+4 more in the same filing8-K 2.03 ↗
- May 8, 24Took on a new financial obligation+3 more in the same filing8-K 2.03 ↗
5 senior executive changes2023 – 2024show all 5hide
- Feb 29, 24A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- Dec 21, 23A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Oct 10, 23A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Sep 26, 23A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jun 20, 23A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
2 older filings not shown · The record reaches back to Jun 3, 11.
Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.
- Jun 29, 17Restructuring plan with committed costs+1 more in the same filing8-K 2.05 ↗
The full record holds 3 stress filings.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Pedro Escudero7.3%Mar 11, 26SCHEDULE 13D/A ↗8 co-filers on this document — the figure is the largest single stake, not their sum.
- Doma Perpetual Capital Management LLC6.8%Dec 30, 25SCHEDULE 13D/A ↗6 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BlackRock, Inc.15.2%Mar 31, 25SCHEDULE 13G/A ↗
- Vanguard Portfolio Management6.4%Mar 31, 26SCHEDULE 13G ↗
- STATE STREET CORPORATION5.2%Jun 30, 26SCHEDULE 13G ↗
- Vanguard Capital Management5.2%Mar 31, 26SCHEDULE 13G ↗
- Dimensional Fund Advisors LP5.1%Mar 31, 26SCHEDULE 13G ↗
show 3 more holdershide
- Renaissance Technologies LLC5.0%Jul 1, 25SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- Pacer Advisors, Inc.1.3%Mar 31, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
- Millennium Management LLC0.7%Mar 31, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Oct 8, RIKER LAUREN filed notice of intent to sell up to $218K. That is about 0.02% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $218K on Oct 8, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+1 more recent notices · 1 with a later sale
- Oct 8, 26Sell$218KLAUREN RIKERSenior Vice President, Finance↗
- Aug 17, 26Sell$71KJONATHAN SLONINChief Medical Officer↗
- Jun 11, 26Sell$144KLAUREN RIKERSenior Vice President, Finance↗
- Jun 4, 26Sell$228KKRISTEN WILLIAMSChief Administrative Officer↗
- Apr 23, 26Sell$326KShawn CrossChief Financial Officer↗
- Apr 22, 26Sell$38KShawn CrossChief Financial Officer↗
- Apr 21, 26Sell$71KShawn CrossChief Financial Officer↗
- Apr 20, 26Sell$194KShawn CrossChief Financial Officer↗
- Mar 17, 26Sell$11KMark Froimson↗
- Mar 17, 26Sell$74KJONATHAN SLONINChief Medical Officer↗
- Feb 2, 26Sell$270KKRISTEN WILLIAMSChief Administrative Officer↗
- Feb 2, 26Sell$83KLAUREN RIKERSenior Vice President, Finance↗
There is 1 more transaction in this stretch.
Stock compensation, tax and giftsshow the 27 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Oct 8, 26Compensation$194KLAUREN RIKERSenior Vice President, Finance↗
- Jun 10, 26Compensationamount n/aLaura Brege↗
- Jun 10, 26Compensationamount n/aMark Froimson↗
- Jun 10, 26Compensationamount n/aMARCELO BIGAL↗
- Jun 10, 26Compensationamount n/aMICHAEL J. YANG↗
- Jun 10, 26Compensationamount n/aAlethia Young↗
- Jun 10, 26Compensationamount n/aCHRISTOPHER CHRISTIE↗
- Jun 10, 26Compensationamount n/aSamit Hirawat↗
- Jun 3, 26Tax$190KKRISTEN WILLIAMSChief Administrative Officer↗
- Jun 3, 26Tax$106KJONATHAN SLONINChief Medical Officer↗
- Jun 3, 26Tax$71KLAUREN RIKERSenior Vice President, Finance↗
- Apr 23, 26Compensation$213KShawn CrossChief Financial Officer↗
- Apr 22, 26Compensation$25KShawn CrossChief Financial Officer↗
- Apr 21, 26Compensation$47KShawn CrossChief Financial Officer↗
- Apr 20, 26Compensation$127KShawn CrossChief Financial Officer↗
- Feb 11, 26Compensationamount n/aFrank D. LeeChief Executive Officer↗
- Feb 11, 26Compensationamount n/aJONATHAN SLONINChief Medical Officer↗
- Feb 11, 26Compensationamount n/aLAUREN RIKERSenior Vice President, Finance↗
- Feb 11, 26Compensationamount n/aBrendan TeehanChief Commercial Officer↗
- Feb 11, 26Compensationamount n/aKRISTEN WILLIAMSChief Administrative Officer↗
- Feb 11, 26Compensationamount n/aShawn CrossChief Financial Officer↗
- Jan 30, 26Tax$852KFrank D. LeeChief Executive Officer↗
- Jan 30, 26Tax$106KBrendan TeehanChief Commercial Officer↗
- Jan 30, 26Tax$127KJONATHAN SLONINChief Medical Officer↗
- Jan 30, 26Tax$352KKRISTEN WILLIAMSChief Administrative Officer↗
- Jan 30, 26Tax$57KLAUREN RIKERSenior Vice President, Finance↗
- Jan 2, 26Tax$227KFrank D. LeeChief Executive Officer↗
The full record holds 178 transactions and goes back to Jan 4, 23.
Its sector and its market
Pacira BioSciences Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Pacira BioSciences Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Pacira BioSciences Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- Series with incidents in the period; the chart shows what could be kept.
- SEC records
- 1,212 documents on file, from Feb 2, 2011 to Oct 13, 2026.
- Company description
- No description available.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.